Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Humacyte (HUMA) EBITDA Margin (2025)

Humacyte has reported EBITDA Margin over the past 1 years, most recently at 6595.07% for Q4 2025.

  • Quarterly results put EBITDA Margin at 6595.07% for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was 2297.74% (changed N/A YoY), and the annual figure for FY2025 was 5304.22%, changed.
  • EBITDA Margin for Q4 2025 was 6595.07% at Humacyte, down from 2325.37% in the prior quarter.
  • Over the last five years, EBITDA Margin for HUMA hit a ceiling of 7570.41% in Q1 2025 and a floor of 12510.96% in Q2 2025.